UModerna, ubhengeze namhlanje ukuba uMphathiswa woKutya kunye noKhuseleko lweziyobisi eKorea (MFDS) ukhuphe isigunyaziso sokuthengisa iSpikevax®, isitofu sokugonya seModerna se-COVID-19 (mRNA-1273) esenziwa yiSamsung Biologics, iCDMO ehamba phambili yehlabathi ebonelela ngesiphelo esidityanisiweyo ngokupheleleyo- ukuphelisa uphuhliso lwekhontrakthi kunye neenkonzo zokwenza.
Olu gunyaziso lwentengiso lufunyenwe yiModerna Korea luvumela ngokusemthethweni iyeza leModerna le-COVID-19 elenziwe kwindawo yemveliso yamayeza yasekhaya yeSamsung Biologics ukuba isasazwe ngaphakathi eKorea kwaye ithunyelwe kwamanye amazwe.
IModerna Korea yenza isicelo sogunyaziso olupheleleyo lwentengiso ye-Spikevax® kunye ne-MFDS ekuqaleni kukaNovemba kwaye yasifumana ngempumelelo kwisithuba senyanga.
IiPhilippines kunye neColombia zigunyazise ukusetyenziswa ngokungxamisekileyo kogonyo lweModerna COVID-19 olwenziwe yiSamsung Biologics ngoNovemba 26 nangoDisemba 2, ngokulandelelanayo.
“Sibulela uMphathiswa woKutya kunye noKhuseleko lweziyobisi eKorea ngesigqibo sabo sokuvuma olu gunyaziso lwentengiso. Intsebenziswano yethu neSamsung Biologics yokwenziwa kokugqiba nokugqiba iyeza lokugonya leModerna COVID-19 liyasinceda ukuba siqhubeke nokunyusa umgangatho wethu wokuvelisa ngaphandle kwe-US, utshilo uStéphane Bancel, iGosa eliLawulayo leModerna. "Kunye namaqabane ethu emveliso, sihlala sizibophelele ekoyiseni ubhubhane we-COVID-19."
"Esi sisiganeko esibalulekileyo ngokwenene njengoko sikwazile ukukhawulezisa inkqubo yokwamkelwa ngokusondeleyo nangokukhawuleza kwentsebenziswano kunye norhulumente waseKorea kunye neModerna, ngakumbi phantsi kovavanyo olungqongqo lwe-MFDS kuvavanyo lokuqala lokwenziwa kogonyo lwe-mRNA eKorea," utshilo uJohn. Rim, i-CEO ye-Samsung Biologics. “Sikwanebhongo ngokubonisa ukuzibophelela kwethu ekuboneleleni ngomgangatho kunye nokubalula kuzo zonke iinkqubo zethu, kwaye siya kuqhubeka sisebenza ngokusondeleyo nomxhasi wethu ukubonelela ngeemveliso ngokuzinzileyo ngakumbi ngenxa yokubaluleka okukhulayo kunye nemfuno yogonyo kumlo ochasene ne-COVID. -19 ubhubhani. "
IModerna inamaqabane amaninzi anobuchule bokwenza ukugqiba ukwenza. E-US, oku kubandakanya Catalent, Inc. (NYSE: CTLT), Baxter BioPharma Solutions kwaye Sanofi (Nasdaq: SNY). Ngaphandle kwe-US, oku kubandakanya rovi (BME: ROVI) eSpain, I-Recipharm eFransi kwaye I-Samsung Biologics (KRX: 207940.KS) eKorea.
Malunga neModerna
Kwiminyaka eli-10 ukusukela oko yaqalwa, iModerna itshintshile ukusuka kwibakala lophando lwesayensi yenkampani yokuqhubela phambili iinkqubo kwindawo yesithunywa i-RNA (mRNA), ukuya kwishishini elineepotfoliyo ezahlukeneyo zekliniki zokugonya kunye nonyango kwiindlela ezisixhenxe, ipotifoliyo yepropathi enomgangatho ophezulu wokuqonda. kwiindawo ezibandakanya i-mRNA kunye ne-lipid nanoparticle formulation, kunye neplanti yokuvelisa edibeneyo evumela ukuba zombini imveliso yeklinikhi kunye neyorhwebo kwinqanaba kunye nesantya esingazange sibonwe ngaphambili. IModerna igcina umanyano kunye noluhlu olubanzi lorhulumente wasekhaya naphesheya kunye nabasebenzisana nabo kwezorhwebo, oluvumele ukusukelwa kokubini isayensi eyophula umhlaba kunye nokukalwa ngokukhawuleza kwemveliso. Kutshanje, amandla kaModerna adibene ukuze avumele ukusetyenziswa okugunyazisiweyo kwesinye sezitofu zokuqala kunye nezona zisebenzayo ngokuchasene nobhubhani we-COVID-19.
Iqonga le-Moderna le-mRNA yakhela kwinkqubela phambili eqhubekayo kwisayensi ye-mRNA esisiseko kunye nesetyenzisiweyo, itekhnoloji yonikezelo kunye nokuveliswa, kwaye ivumele uphuhliso lonyango kunye nogonyo lwezifo ezosulelayo, i-immuno-oncology, izifo ezinqabileyo, izifo zentliziyo kunye nezifo ezizimelayo. UModerna unikwe igama lokuba ngumqeshi ophambili we-biopharmaceutical ngu inzululwazi kule minyaka isixhenxe idlulileyo. Ukuze ufunde ngakumbi, ndwendwela www.ibalauni.com.
Malunga neSamsung Biologics Co., Ltd.
I-Samsung Biologics (KRX: 207940.KS) yi-CDMO edityaniswe ngokupheleleyo ebonelela ngophuhliso lwekhontrakthi yangoku, ukuvelisa, kunye neenkonzo zovavanyo lwaselabhoratri. Ngemvume eqinisekisiweyo yolawulo, esona sikhundla sikhulu, kunye nesona siphumo sikhawulezayo, i-Samsung Biologics liqabane eliphumelele ibhaso elikhethiweyo kwaye liyakwazi ngokukodwa ukuxhasa uphuhliso kunye nokuveliswa kweemveliso zebhayoloji kwinqanaba ngalinye lenkqubo ngelixa ihlangabezana neemfuno eziguqukayo ze-biopharmaceutical. iinkampani zehlabathi. Ngolwazi oluthe vetshe, ndwendwela www.samsungbiologicals.com.
INTO ONOKUYITHATHA KWELI NQAKU:
- About ModernaIn 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed.
- With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.
- “We were also proud to demonstrate our commitment to providing both quality and agility throughout our processes, and will continue to work closely with our client to stably supply the products especially in light of the increasing importance and demand for vaccines in the battle against the COVID-19 pandemic.
